方法：观察2018-02/2021-02连续3mo接受康柏西普治疗的糖尿病性黄斑水肿患者38例43眼。分析对比敏感度(CS)从基线到治疗12wk的平均变化，比较治疗前后最佳矫正视力(BCVA)、视网膜中央厚度(CRT)和视觉功能问卷(NEIVFQ-25)评分。

结果：玻璃体腔注射康柏西普注射液后，CS从基线的1.060±0.14增加到治疗12wk的1.47±0.31(P<0.05)。基线时BCVA(LogMAR)为0.535±3.32，治疗12wk时为0.333±0.11(P<0.05)。基线时CRT为369.45±36.42μm，治疗12wk时降至226.53±39.48μm(P<0.05)。CRT与BCVA测量变化及CS的改善均无相关关系。患者30例(79%)从基线至第12wk，NEIVFQ-25综合评分总体改善，6例(16%)无变化，2例(5%)综合评分总体下降。

结论：康柏西普注射液治疗糖尿病性黄斑水肿，可明显改善患者的视功能，提高视觉相关生活质量。

METHODS: The average change of contrast sensitivity(CS), best corrected visual acuity(BCVA), central retinal thickness(CRT)and NEIVFQ-25 score were observed for 3mo after intravitreal injection of conbercept in 43 eyes of 38 patients with diabetic macular edema.

RESULTS: The mean CS increased from(1.060±0.14)units to(1.47±0.31)units at 12wk after intravitreal injection of conbercept(P<0.05). The average LogMAR BCVA decreased significantly from 0.535±3.32 to 0.333±0.11 at 12wk(P<0.05), and the average CRT decreased significantly from 369.45±36.42μm to 226.53±39.48μm at 12wk(P<0.05). There is not a correlation between the changes in CRT and BCVA and the improvement of CS. The NEIVFQ-25 score improved in 30 cases(79%)from baseline to 12wk. 6 cases(16%)had no change in the NEIVFQ-25 score, and 2 cases(5%)declined in the NEIVFQ-25 score.

CONCLUSION: The treatment of conbercept injection for diabetic retinal macular edema can significantly improve the visual function and the quality of life.